Docel 120mg Injection (Docetaxel)

Docel 120mg Injection is a chemotherapy-based anticancer medicine. It is prescribed to treat multiple types of cancer, such as breast cancer, non-small cell lung cancer, prostate cancer and cancers of the head and neck. It contains docetaxel as an active ingredient.

Docel 120mg works as an antimicrotubule agent, as it interferes with the microtubule structures which help in cancer cell division and multiplication. Results in slowing down the growth of cancer cells and killing them. This injection is given by a qualified medical professional.

Breast Cancer

Side effects are undesirable symptoms that can result from any medical treatment. Like any other medicine, Docel 120mg Injection (Docetaxel 120mg) also causes some adverse impact on the body, most of which resolves without any medical attention. 

However, if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately.​

Some common side effects include:
● Low blood platelets
● Hair loss
● Nerve damage
● Neuropathy
● Numbness of extremity
● Taste change
● Breathlessness
● Constipation
● Edema (swelling)
● Infection
● Loss of appetite
● Muscle pain
● Nail disorder
● Pain
● Weakness

Docel 120mg Injection (Docetaxel 120mg) is available in injection form and is advised to be taken as per the doctor's prescription. It can only be given intravenously by a doctor or nurse under strict medical supervision. Taking this injection in the wrong way may give you severe side effects.

In case of overdose, contact your healthcare provider or doctor, and they will provide you with medical attention. Missing or overdosing will impact the overall health of the patients and may also have side effects. So, it is always advisable to follow the prescription of the doctor strictly.

● Van Laar, E. S., Weitman, S., MacDonald, J. R., & Waters, S. J. (2004). Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models. The Prostate, 59(1), 22-32.
● Wang, Y., Lieberman, R., Pan, J., Zhang, Q., Du, M., Zhang, P., ... & Wang, L. (2016). miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1. Molecular cancer, 15(1), 70.
● Yonemura, Y., Endou, Y., Bando, E., Kuno, K., Kawamura, T., Kimura, M., ... & Sugarbaker, P. H. (2004). Effect of intraperitoneal administration of docetaxel on peritoneal dissemination of gastric cancer. Cancer letters, 210(2), 189-196.
● Yan, M., Wang, J., Ren, Y., Li, L., He, W., Zhang, Y., ... & Li, Z. (2019). Over-expression of FSIP1 promotes breast cancer progression and confers resistance to docetaxel via MRP1 stabilization. Cell death & disease, 10(3), 204.
● de Bree, E., Rosing, H., Beijnen, J. H., Romanos, J., Michalakis, J., Georgoulias, V., & Tsiftsis, D. D. (2003). Pharmacokinetic study of docetaxel in intraoperative hyperthermic ip chemotherapy for ovarian cancer. Anti-cancer drugs, 14(2), 103-110.